It's absolutely a fair question. eom

http://209.85.165.104/search?q=cache:jWD-x5FkdOEJ:www.flsenate.gov/cgi-bin/View_Page.pl%3FTab%3Dlegi...

How the frog Chytrid fungus spreads

The Chytrid fungus only attacks the parts of a frog's skin that have keratin in them. Tadpoles can be infected around their mouths, but this isn't enough to kill them. It's only when they start turning into frogs, and grow keratin in other areas, that the Chytrid fungus can spread throughout their bodies.

They may then die from the disease - but not before they've hopped and swum around, spreading the fungal spores to other ponds and streams. Once a pond has become infected with Chytrid fungus, the fungus may stay in the water forever. This means it's very important not to move frogs from one area to another.

froggy, you're not upset about those shares "NOT" coming on the market in 2007...are you? Pretty slick...dont'cha stink? Letting the notes default...

croak, you sound a little ruffled. Is your stomach upset?

At first it was thought that frogs could not throw up, but then it was discovered on a space mission that a frog can throw up. The frog throws up its stomach first, so the stomach is dangling out of its mouth. The frog then uses its forearms to dig out all of the stomach's contents and then swallows the stomach back down again.

In the 2004 agreement with Dutchess, the notes were to be paid by "put notices" issued to Dutchess. The put notices are discounted and the "difference" is owed. Shares are issued and Dutchess sells them in the open market. By defaulting on the notes they've effectively "delayed" the issuance of shares for 3 years.

I don't know why they haven't kept up payments to Harvard and terminated the services agreement with KBI-Biopharma.

In the licensing agreement "matching funds" are stipulated for R&D. Maybe this is strong arm tactics to include monies for the "production" of PT-401 as well. How's that for spin? JMHO

I hate filings. Why can't they put all pertinent info. in the same section. It seems all notes due from Dec. 2006 to June 2007 were satisfied by issuance of convertible debentures. I say issuance...that is at the behest of Dutchess...the default in Dec. gets them the 30% of face value or potentially $2,143,500 from all the notes. I'll take it as good news that these shares aren't going to hit the market for another three years.

Dutchess December Note

On December 22, 2005, we issued to Dutchess a promissory note in the amount of $1,380,000. The note was due and payable in full on December 15, 2006. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement (see Note K below). The required repayments under the note increase if we raise additional capital during the term of the note (other than capital raised under facilities in existence as of the date of the note). The note was not paid in full as of December 31, 2006. See Dutchess Notes Default discussion below.

In connection with the note issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on December 15, 2010. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’ option at a conversion price equal to the lesser of 75% of the lowest closing bid price during the 15 trading days prior to the conversion date or $0.022. The discount recorded on the $330,000 convertible debenture is being amortized to interest expense over the term of this note using the effective method. Amortization during the year ended December 31, 2006 and 2005 amounted to $43,062 and $114, respectively. At December 31, 2006, there was $286,824 of unamortized discount related to the debenture.


Dutchess March 2006 Note

On March 6, 2006, we issued to Dutchess a promissory note in the amount of $1,500,000 for a purchase price of $1,200,000. The note is due and payable in full on March 6, 2007. Other than the $300,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement (See Note K below). The required repayments under the note increase if we raise additional capital during the term of the note (other than capital raised under facilities in existence as of the date of the note).

In connection with the note, we paid Dutchess a facility fee of $65,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on March 6, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’ option at a conversion price of $0.01. The $65,000 fee was included in the calculation to allocate the fair market value to the March note payable and convertible debenture transaction. We recorded this transaction in accordance with SFAS 155, “Accounting for Certain Hybrid Financial Instruments”. We also paid $48,000 of fees to Athena which were recorded as deferred financing fees and are being amortized to interest expense over the term of the note.


Dutchess April 2006 Note




On April 17, 2006, we issued to Dutchess a promissory note in the amount of $1,470,000 for a purchase price of $1,175,000. The note is due and payable in full on April 17, 2007. Other than the $295,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement (See Note K below). The required repayments under the note increase if we raise additional capital during the term of the note (other than capital raised under facilities in existence as of the date of the note).


In connection with the note, we paid Dutchess a facility fee of $65,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $320,000 payable on April 17, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’ option at a conversion price of $0.01. The $65,000 fee was included in the calculation to allocate the fair market value to the April note payable and convertible debenture transaction. We recorded this transaction in accordance with SFAS 155, “Accounting for Certain Hybrid Financial Instruments”. We also paid $47,000 of fees to Athena which were recorded as deferred financing fees and are being amortized to interest expense over the term of the note.




The discount of $378,185 to the debt instrument and $301,890 to the convertible debenture is being amortized to interest expense over the term of this note using the effective interest method. Amortization during the year ended December 31, 2006 amounted to $268,617 on the note and $9,097 on the convertible debenture. At December 31, 2006, there was $109,568 and $292,793 of unamortized discount related to the note and debenture, respectively.




Dutchess May 2006 Note




On May 18, 2006, we issued to Dutchess a promissory note in the amount of $1,300,000 for a purchase price of $1,000,000. The note is due and payable in full on May 18, 2007. Other than the $300,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement (See Note K below). The required repayments under the note increase if we raise additional capital during the term of the note (other than capital raised under facilities in existence as of the date of the note).




In connection with the note, we paid Dutchess a facility fee of $90,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on May 18, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’ option at a conversion price of $0.01. The $90,000 fee was included in the calculation to allocate the fair market value to the May note payable and convertible debenture transaction. We recorded this transaction in accordance with SFAS 155, “Accounting for Certain Hybrid Financial Instruments”. We also paid $40,000 of fees to Athena which were recorded as deferred financing fees and are being amortized to interest expense over the term of the note.




The discount of $399,255 to the debt instrument and $320,820 to the convertible debenture is being amortized to interest expense over the term of this note using the effective interest method. Amortization during the year ended December 31, 2006 amounted to $234,624 on the note and $5,191 on the convertible debenture. At December 31, 2006, there was $164,631 and $315,629 of unamortized discount related to the note and debenture, respectively.




Dutchess June 2006 Note




On June 29, 2006, we issued to Dutchess a promissory note in the amount of $1,495,000 for a purchase price of $1,150,000. The note is due and payable in full on June 29, 2007. Other than the $345,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement (See Note K below). The required repayments under the note increase if we raise additional capital during the term of the note (other than capital raised under facilities in existence as of the date of the note).




In connection with the note, we paid Dutchess a facility fee of $90,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $373,750 payable on June 29, 2011. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’ option at a conversion price of $0.01. The $90,000 fee was included in the calculation to allocate the fair market value to the June note payable and convertible debenture transaction. We recorded this transaction in accordance with SFAS 155, “Accounting for Certain Hybrid Financial Instruments”. We also paid $46,000 of fees to Athena which were recorded as deferred financing fees and are being amortized to interest expense over the term of the note.

The discount of $446,825 to the debt instrument and $362,000 to the convertible debenture is being amortized to interest expense over the term of this note using the effective interest method. Amortization during the year ended December 31, 2006 amounted to $203,633 on the note and $4,856 on the convertible debenture. At December 31, 2006, there was $243,192 and $357,144 of unamortized discount related to the note and debenture, respectively.

Dutchess Notes Default


If there is an event of default with any promissory note to Dutchess, Dutchess has the right to convert the residual amount to a convertible debenture which can convert into our common stock at the lesser of (i) fifty percent of the lowest closing bid price during the fifteen trading days immediately preceding the maturity date or (ii) 100% of the lowest bid price for the twenty trading days immediately preceding the conversion date. At December 31, 2006, the Dutchess December Note was not paid when due. Dutchess had the right to switch the residual amount of $581,158 on the Dutchess December Note to a three-year convertible debenture; however, they had not exercised this right at December 31, 2006 nor at the time this report was issued.


We are in default of each of the Dutchess Notes due to not making the minimum principal payments. Dutchess has the right to charge us liquidated damages of up to 30% of the face amount of these notes. Dutchess has not exercised this right at December 31, 2006 nor at the time this report was issued. At December 31, 2006, we recorded a default penalty accrual in the amount of $2,143,500 for these potential liquidated damages. This is an estimate based upon the maximum amount that Dutchess could charge us and this estimate may change with time.

Shareholders

As February 15, 2007 there were 1,034 owners of record of our common stock.

You're right Michiko... Coors, Anheuser-Busch, Miller, Schlitz, Pabst, NOW those are some GOOD GERMAN LAGERS!!!

cloud, how do you continue research without product? I'm going to e-mail the company on this.

chris, they paid the "good debt".

Clientis line of credit

On October 3, 2006, we entered into a line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 400,000 Swiss Francs with an annual interest rate of 4%, and the line of credit terminates on October 6, 2007. On October 3, 2006, we borrowed 400,000 Swiss Francs on the line of credit. The amount borrowed on this line of credit was paid back during January 2007.

On October 26, 2006, we entered into a line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 160,000 Euros with an annual interest rate of 5%, and the line of credit terminates on October 26, 2007. On October 27, 2006, we borrowed 160,000 Euros on the line of credit. The amount borrowed on this line of credit was paid back during January 2007

They defaulted on the crap. It was worth it to the company to NOT issue additional shares to pay the notes. That is certainly good news. The damages accrued are negotiable. And with new financing and restructuring Dutchess will probably participate and wave damages.

Dutchess Default

We are in default of each of the Dutchess Notes due to not making the minimum principal payments. Dutchess has the right to charge us liquidated damages of up to 30% of the face amount of these notes. Dutchess has not exercised this right at December 31, 2006 nor at the time this report was issued. At December 31, 2006, we had accrued $2,143,500 for these potential liquidated damages. This is an estimate based upon the maximum amount that Dutchess could charge us and this estimate may change with time.

This is the "new agreement" b/w Athena and Dnaprint. They are to be considered the "Investment Bankers" in the restructuring.

January 22, 2007

Richard Gabriel, CEO and

Hector Gomez, M.D., Ph. D., Chairman

DNAP Genomics, Inc.

1621 W. University Parkway

Sarasota, FL 34243

Gentlemen:

This letter agreement (the “Agreement”) shall confirm the engagement of Athena Capital Partners, Inc. (“Athena”) by DNAPrint Genomics, Inc. and any of its subsidiaries and affiliates (hereinafter referred to collectively as the “Company”) as the Company’s exclusive investment banking agent to:

1.Arrange and negotiate a private placement of securities, issued by the Company and/or any of its subsidiaries or affiliates (“Private Placement”), in the form of common stock, convertible preferred stock, convertible debt, debt with warrants, or any other equity-linked securities (the “Equity Securities”);

2.To provide merger & acquisition assistance (“M&A Transaction”) as requested;

3.Arrange and negotiate senior and/or junior debt (“Debt Financing”)

4.Advise and provide services to the Company on an as-requested basis. The type of additional services Athena will include, but not be limited to: (1) to identify, conduct due diligence, research and/or negotiate on behalf of the Company with investor relations firms, market makers, stock exchanges. Advise and assist the Company with respect to other financial transactions as requested. Provide other investment banking and financial advisory services to the Company as deemed appropriate (“Additional Services”).

The services enumerated in 1, 2, 3 and 4 will hereinafter collectively be referred to as “Investment Banking Services”.

upon the closing of a Transaction (i.e. a Private Placement, Debt Financing or M&A Transaction), a transaction fee (the “Transaction Fee”) payable in cash to Athena, except as provided in Exhibit A – Carve Outs, in an amount as follows:

a.

Private Placement of Equity Securities – a cash fee based on the amount of the Aggregate Consideration (as defined below) paid for the Equity Securities by Investors as outlined below:

(i) 10 of the first $5,000,000,

(ii) 8 of amounts from $5,000,001 to $10,000,000,

(iii) 7 of amounts from $10,000,001 to $15,000,000,

cont'd

(iv) 6 of amounts from $15,000,001 to $20,000,000,

(v) 5 of all amounts in excess of $20,000,000.

b.

Debt Financing – a cash fee of the total amount of the Debt Financing as follows:

(i) 5 of the first $2,000,000,

(ii) 3 of amounts from $2,000,001 to $5,000,000,

(iii) 2.5 of amounts from $5,000,001 to $20,000,000,

(iv) 2 of amounts in excess of $20,000,000.

c.

M&A Transactions – a cash fee of the total value of the transaction including contingent payments as follows:

(i) 5 of the first $10,000,000

(ii) 4 of transaction value between $10,000,001 and $20,000,000,

(iii) 3 of transaction value between $20,000,001 and $50,000,000,

(iv) 2 of transaction value between $50,000,001 and above.

(iii.)

Fees for any other financial advisory services will be negotiated in good faith as the need arises.

(b)

In addition to the fees payable to Athena hereunder and regardless of whether the sale of any of the Equity Securities or M&A Transaction is consummated or Debt Financing is placed, the Company shall reimburse Athena, upon request made from time to time, for all of Athena’s out-of-pocket expenses incurred in connection with this engagement, including the fees, disbursements and other charges of Athena’s legal counsel. The Company acknowledges that Athena has a monthly administrative charge (the administrative charge includes small dollar charges for items such as long distance telephone calls, regular mail postage, photocopies, etc. It does not include charges such as FedEx charges or charges for conference calls hosted by a third party vendor) of $400 (beginning September 1, 2006), in addition to specific direct reimbursable charges. All individual expenses in excess of $500.00 will be pre-approved by the Company.

cont'd

(iv) 6 of amounts from $15,000,001 to $20,000,000,

(v) 5 of all amounts in excess of $20,000,000.

b.

Debt Financing – a cash fee of the total amount of the Debt Financing as follows:

(i) 5 of the first $2,000,000,

(ii) 3 of amounts from $2,000,001 to $5,000,000,

(iii) 2.5 of amounts from $5,000,001 to $20,000,000,

(iv) 2 of amounts in excess of $20,000,000.

c.

M&A Transactions – a cash fee of the total value of the transaction including contingent payments as follows:

(i) 5 of the first $10,000,000

(ii) 4 of transaction value between $10,000,001 and $20,000,000,

(iii) 3 of transaction value between $20,000,001 and $50,000,000,

(iv) 2 of transaction value between $50,000,001 and above.

(iii.)

Fees for any other financial advisory services will be negotiated in good faith as the need arises.

(b)

In addition to the fees payable to Athena hereunder and regardless of whether the sale of any of the Equity Securities or M&A Transaction is consummated or Debt Financing is placed, the Company shall reimburse Athena, upon request made from time to time, for all of Athena’s out-of-pocket expenses incurred in connection with this engagement, including the fees, disbursements and other charges of Athena’s legal counsel. The Company acknowledges that Athena has a monthly administrative charge (the administrative charge includes small dollar charges for items such as long distance telephone calls, regular mail postage, photocopies, etc. It does not include charges such as FedEx charges or charges for conference calls hosted by a third party vendor) of $400 (beginning September 1, 2006), in addition to specific direct reimbursable charges. All individual expenses in excess of $500.00 will be pre-approved by the Company.

upon the closing of a Transaction (i.e. a Private Placement, Debt Financing or M&A Transaction), a transaction fee (the “Transaction Fee”) payable in cash to Athena, except as provided in Exhibit A – Carve Outs, in an amount as follows:

a.

Private Placement of Equity Securities – a cash fee based on the amount of the Aggregate Consideration (as defined below) paid for the Equity Securities by Investors as outlined below:

(i) 10 of the first $5,000,000,

(ii) 8 of amounts from $5,000,001 to $10,000,000,

(iii) 7 of amounts from $10,000,001 to $15,000,000,

ann, Michiko, that post was in Dutch!! And, yes...I drink Heineken!

M & A Target:


The Company shall pay to Athena all fees to Athena as described in paragraph 4(a) of this Agreement in the event that at any time prior to the expiration of 12 months after the Termination Date a Transaction is consummated whereby (i) any of the Equity Securities (or instruments substantially similar to the Equity Securities) or substantially all the assets of the Company are sold to any Investor identified and/or contacted during the Authorization Period; (ii) any Debt Financing with any Lender identified and/or contacted during the Authorization Period or (iii) any M&A Transaction is consummated with a target identified and/or contacted (“M&A Target”) during the Authorization Period.

(d)

If a Transaction has been consummated and one or more subsequent Transactions contemplated in this engagement letter (each, a “Subsequent Transaction”) are consummated by the Company (or any affiliate or subsidiary thereof) within 12 months from the closing date of the initial Transaction with any Investor, Lender or M&A Target identified and/or contacted during the Authorization Period, Athena shall be entitled to receive fees in amounts and terms consistent with those outlined in paragraph 4(a) above (“Subsequent Fee”) .

(e)

The definition of “Aggregate Consideration” for purposes of calculating Athena’s fee shall be deemed to include the aggregate fair market value of all cash and other consideration paid for the Equity Securities (or instruments substantially similar to the Equity Securities) by the Investors, as well as any amounts paid in escrow and amounts payable in the future. The fair market value of any non-cash consideration will be the value determined by the Company and Athena at or prior to the date of the applicable Transaction. The portion of Athena’s fee relating to any future payments shall be calculated and paid when and as the future payments are made.

(f)

Upon the closing of a Transaction or a Subsequent Transaction, all proceeds from the closing (and subsequent payments resulting from the Transaction or Subsequent Transaction) shall be placed in an escrow account with The Palm Bank, Tampa, Florida for retention and distribution in accordance with an Escrow Agreement substantially in the form attached to this Agreement as “Exhibit B – Escrow Agreement.

(g)

As described above, the Transaction Fee and the Subsequent Fee are payable to Athena by the Company upon the closing of a Transaction and a Subsequent Transaction, respectively, and the reimbursement of Athena’s out-of-pocket expenses is payable by the Company from time to time upon the request of Athena. The Company will pay Athena, at a rate equal to twelve percent (12) per year, a monthly late payment charge (the “Late Payment Charge”) on the unpaid balance of any fees or expenses not timely paid in full. With respect to any unpaid portion of the Transaction Fee, the Late Payment Charge will be computed from the date of the closing of the Transaction or the Subsequent Transaction, as applicable, until payment in full. With respect to the unpaid portion of any of Athena’s out-of-pocket expenses, the Late Payment charge will be computed from thirty (30) days after the issuance of Athena’s invoice until payment in full of the out-of-pocket expenses.

Clientis line of credit




On October 3, 2006, we entered into a line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 400,000 Swiss Francs with an annual interest rate of 4%, and the line of credit terminates on October 6, 2007. On October 3, 2006, we borrowed 400,000 Swiss Francs on the line of credit. The amount borrowed on this line of credit was paid back during January 2007.




On October 26, 2006, we entered into a line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 160,000 Euros with an annual interest rate of 5%, and the line of credit terminates on October 26, 2007. On October 27, 2006, we borrowed 160,000 Euros on the line of credit. The amount borrowed on this line of credit was paid back during January 2007

To provide merger & acquisition assistance (“M&A Transaction”) as requested

CONFIDENTIAL




January 22, 2007




Richard Gabriel, CEO and

Hector Gomez, M.D., Ph. D., Chairman

DNAP Genomics, Inc.

1621 W. University Parkway

Sarasota, FL 34243




Gentlemen:




This letter agreement (the “Agreement”) shall confirm the engagement of Athena Capital Partners, Inc. (“Athena”) by DNAPrint Genomics, Inc. and any of its subsidiaries and affiliates (hereinafter referred to collectively as the “Company”) as the Company’s exclusive investment banking agent to:




1.

Arrange and negotiate a private placement of securities, issued by the Company and/or any of its subsidiaries or affiliates (“Private Placement”), in the form of common stock, convertible preferred stock, convertible debt, debt with warrants, or any other equity-linked securities (the “Equity Securities”);

2.

To provide merger & acquisition assistance (“M&A Transaction”) as requested;

3.

Arrange and negotiate senior and/or junior debt (“Debt Financing”) and

4.

Advise and provide services to the Company on an as-requested basis. The type of additional services Athena will include, but not be limited to: (1) to identify, conduct due diligence, research and/or negotiate on behalf of the Company with investor relations firms, market makers, stock exchanges. Advise and assist the Company with respect to other financial transactions as requested. Provide other investment banking and financial advisory services to the Company as deemed appropriate (“Additional Services”).

The services enumerated in 1, 2, 3 and 4 will hereinafter collectively be referred to as “Investment Banking Services”.


Dutchess Default

We are in default of each of the Dutchess Notes due to not making the minimum principal payments. Dutchess has the right to charge us liquidated damages of up to 30% of the face amount of these notes. Dutchess has not exercised this right at December 31, 2006 nor at the time this report was issued. At December 31, 2006, we had accrued $2,143,500 for these potential liquidated damages. This is an estimate based upon the maximum amount that Dutchess could charge us and this estimate may change with time.

david, Iorio is an idiot. You DO NOT PLAY GAMES WHEN SOMEBODY IS GOING TO INVEST $100 MILLION. She should be drawn and quartered, boiled in oil, and stuffed in the IRON MAIDEN.

PORCHES!! PORCHES!!! A hundred million dollar deal with the potential to provide personalized medicines to cancer patients and these wanna'be's are dragging their tails. Iorio can kiss my white.....

Designated Marketing.eom

I sent a request and received an e-mail from Designed Marketing. There were 2 pdf attachments. copy:

DNAPrint™ Genomics, Inc. (“DNAPrint”) develops and markets genetic
testing products and services. The company’s scientists aim their
research towards discovery of DNA analysis solutions to serve clients in
Forensic Science, Genealogical Research, and Pharmaceutical
development. DNAPrint™ Genomics, Inc. is a cutting edge company
with innovative products and solutions that could make a profound impact
on improving our health care and combating crime and terrorism around
the world.
Improving health care: DNAPrint has a breakthrough product
that allows the patient to be tested prior to beginning the drug
treatment to determine whether that drug treatment will be effective
for them based on their specific DNA. This company’s
breakthrough products could make the difference in life or
death in patient. Over 100,000 people die each year from
improper drug treatment. Imagine the demand for this company’s
products when physicians and patients demand DNAPrint’s
products as the new standard practice to optimize the
diagnosis and treatment of their illness.
Combating crime and terrorism: Based on a single piece of
DNA, DNAPrint can provide law enforcement detailed descriptions
and drawings of the suspect. Their products provide “exclusion”
capabilities for investigators, and can narrow a list of suspects from
thousands down to just a few.
Why Invest Now:
• Hunting for the right drug therapy; revolutionized by DNAPrint!
• Hunting for a serial killer; revolutionized by DNAPrint!
• Hundreds of billions of dollars spent on healthcare, and demand
for new services and products is skyrocketing. World-wide
spending for new tools in the fight against terrorism and crime is
skyrocketing.
• Company’s current market value around $4 million, and
Analyst recently estimated this company’s market value at
over $30 million. A potential 700-800% jump in value!!!
As demand for a company’s products skyrocket, typically their sales
and stock price also skyrocket. This is your chance to get in early
stage just before the potential surge in demand, and The Street
realizes the potential of this up and coming company.
DISCLAIMER: Information material sent in response to this card does not constitute an offerin

Valued at more than $28 billion, the global diagnostic market represents strong potential for DNAG

http://72.14.209.104/search?q=cache:be6uajS4ViEJ:www.amalfiresearch.com/report/DNAG.pdf+dnaprint+%22...

In drug discovery and development, pharmocogenomics will couple rational drug design to DNA- and protein-sequence analysis to develop custom pharmacological products based upon individual genetic traits. The computing power required to integrate such functionality into a high throughout drug pipeline is considerable. Leading companies in the pharmacogenomics field include Sequenom, Orchid BioSciences, Genaissance Pharmaceuticals, Compugen Ltd, Illumina, Nanogen, Third Wave Technologies, Interleukin Genetics, Luminex and DNAPrint Genomics.

http://www.biotechstock.com/en-us/pg_16.html

O.K. eom

http://72.14.209.104/search?q=cache:g5QaHKIDqzsJ:www.bio-itworld.com/archive/090902/pharma.html%3Fpa...

DONDERDAG!! Wanneer de hel dit ding toestand is te verwijderen. Ik ben en vermoeid om over mijn geest te verliezen.

JUEVES!!! Cuándo el infierno es esta cosa yendo a quitar. Soy cansado y acerca de perder el juicio.

THURSDAY!!!EOM

Wow!!froggy,he's got your #.ROFL

http://www.nucleabiomarkers.com/products.shtml


http://helicosbio.com/C834F7574754444EA4E6AF4890479955.asp?x=1&ie_key=5CBAD30B0E174904839CA5AE79...

All in all, I am here for the entertainment and expect to be here for the eventual denouement.

regards,
frog

CLOWN... USELESS All in all, I am here for the entertainment and expect to be here for the eventual denouement.

regards,
frog

All in all, I am here for the entertainment and expect to be here for the eventual denouement.

regards,
frog

All in all, I am here for the entertainment and expect to be here for the eventual denouement.

regards,
frog

HEYY! OK..it's FROG II.. Frog's little dopey sidekick...

stock, would you please post to confirm this TIA

In the county journal, m2gen was to have revenues soon...

sam, I never knew what to make out of this...I
ve seen the link before:

The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers.

sam, where is this from. Please post link...TIA

stockholder, could you please explain every word of your post? TIA